Valuation dashboard for Liquidia Corporation (LQDA) with P/E 34.61, P/B 21.58, EV/EBITDA 20.2 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension.
Where would it trade at its usual multiples?
Versus its usual multiples: fairly priced · Current P/E 34.6× · Multiples range: $42.02 · $42.02.
At its sector median (30.7×) $42 (-11%). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Analysis Summary
Liquidia Corporation reported revenue of $158.3M in the most recent fiscal year, growing at a 5-year CAGR of 192.5%.
Trailing-twelve-month margins: gross margin 92.5%, operating margin 37.4%, net margin 30.7%.
At $47.38 (closing price, November 4, 2026), LQDA trades at a P/E of 34.61 and an ROE of 149.64%. Market capitalisation stands at $4.2B.
Balance sheet quality for LQDA: debt-to-equity ratio of 0.66, current ratio of 2.31 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 34.61 |
| Price / Book | 21.58 |
| EV / EBITDA | 20.2 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LQDA | Liquidia Corporation | $4.2B | 34.61 | 21.58 | 149.6% |
| INSM | Insmed Incorporated | $24.1B | 33.14 | -82.7% | |
| UTHR | United Therapeutics Corporation | $26.1B | 23.00 | 4.14 | 19.2% |
| RPRX | Royalty Pharma plc | $30.1B | 50.80 | 3.07 | 9.0% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $12.7B | 165.12 | 12.82 | 8.4% |
| CORT | Corcept Therapeutics Incorporated | $8.6B | 62.38 | 10.13 | 22.9% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $7.6B | 73.37 | 10.58 | 17.3% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | 19.37 | -2.3% |
Price
| Price | $47.38 (closing price, November 4, 2026) |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 149.64% |
| Return on Invested Capital | 46.86% |
| Return on Assets | 26.56% |
| Gross Margin | 92.48% |
| Operating Margin | 37.39% |
| Net Margin | 30.74% |
Related companies: INSM · UTHR · RPRX · 0I3Q.L · CORT · KNSA · 0HF9.L · PBH
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of LQDA: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks